Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Life science alliance · 2020
    CKCharles Kyriakos VorkasHKHarjot Kaur SinghAMAyana MoralesRDRobert DeSimone+6 more →GGGiorgio Ga. Inghirami
    PMID: 33361110PMCID: PMC7768198DOISenior author59 citations
  2. 2
    Blood · 2023
    LYLiron YoffeAMAri M. MelnickOEOlivier ElementoSRShahin RafiiGGGiorgio Ga. Inghirami
    PMID: 35981563PMCID: PMC10082359DOISenior author14 citations
  3. 3
    Cell reports. Medicine · 2025
    PZPaul ZumboLYLiron YoffePGPaola GhioneSPSanjay Patel+8 more →GGGiorgio Ga. Inghirami
    PMID: 40147445PMCID: PMC12047492DOIeCommonsSenior author10 citations

Publications

370 publications

Funding

45 grantsView NIH portfolio on RePORTER ↗

Active

14 grants
  • MPI
    SPORE: Adressing Health Disparities in Lymphoma
    National Cancer Institute · 2025–2030 · via MD Anderson Cancer Center· 2 renewals
    U54CA302435-01
  • Co-I
    Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer
    National Cancer Institute · 2023–2028
    R01CA271915-01A1
  • KP
    Targeting Unmet Needs For B-cell Lymphomas
    Leukemia & Lymphoma Society · 2022–2027
    LLS 7027-23 Project 1
  • Co-I
    Targeting the microenvironment to increase immunity and immunotherapy response in DLBCL
    Leukemia & Lymphoma Society · 2024–2027
    LLS 6695-25
  • MPI
    The impact of changes in chromatin architecture on cancer phenotypes and tumor progression
    National Cancer Institute · 2019–2027 · via New York University· 2 renewals
    P01CA229086-07
  • KP
    Biomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signatures
    Hyundai Hope on Wheels Foundation · 2024–2026
    HHWF 240412-01
  • KP
    Targeting latency switch for the treatment of EBV-associated lymphomas
    American Cancer Society · 2024–2026
    PF-23-1143526-01-IBCD
  • Sub-PI
    Translational Discovery in Peripheral T-Cell Lymphomas
    Leukemia & Lymphoma Society · 2022–2026 · via Memorial Sloan Kettering Cancer Center
    LLS SCOR -7026-21
  • Co-I
    Converting HR+ Breast Cancer Into an Individualized Vaccine
    U.S. Department of Defense · 2019–2026
    W81XWH-19-1-0141
  • Co-I
    Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory
    U.S. Department of Defense · 2021–2026
    W81XWH-21-2-0034
  • Co-I
    Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
    National Cancer Institute · 2024–2026
    P01CA272295-02
  • Co-I
    The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
    National Cancer Institute · 2015–2026 · via Mayo Clinic· 2 renewals
    U01CA195568-09
  • Co-I
    Targeting Latency Switch in EBV+ Lymphomas
    National Cancer Institute · 2022–2026
    R37CA262517-01A1
  • Co-I
    Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
    National Cancer Institute · 2019–2025
    R01CA242069-01A1
Completed grants (31)
  • KP
    Characteristics and Outcomes of Patients with Follicular Lymphoma with at Least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers within the LEO Cohort
    Genentech, Inc. · 2022–2025 · via Mayo ClinicContract
    SRA 223443-01
  • Co-I
    Mechanism-Based Targeting of Mantle Cell Lymphoma
    National Cancer Institute · 2018–2025
    P01CA214274-05
  • Sub-PI
    Genetic Mutational and Expression Landscape of Cutaneous CD30+ Lymphoproliferative Disorders.
    National Cancer Institute · 2023–2025 · via Beckman Research Institute of the City of Hope
    R21CA259932-02
  • Co-I
    The effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity and clinical outcomes of COVID-19
    National Institute of Allergy and Infectious Diseases · 2024–2024
    R21AI182901-01
  • KP
    Immunologic Eradication of Myeloproliferative Neoplasm Stem Cells
    Daedalus Fund for Innovation (Weill Cornell) · 2022–2024BioPharma Alliance
    BP 226449-02
  • KP
    Generation of fully humanized murine avatars of B-ALL patients for the study of refractoriness and relapse in a bedside approach
    American Italian Cancer Foundation · 2023–2024
    AICF 230997-01
  • Sub-PI
    Molecular Diagnosis, Prognosis and Therapeutic Targets in Lymphoma (Core 3)
    National Cancer Institute · 2018–2024 · via Mayo Clinic
    P01CA229100-05
  • Co-I
    Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer
    American Association for Cancer Research · 2017–2024 · via Sloan-Kettering Institute for Cancer Research
    SU2C-AACR-DT22-17
  • PI
    Vividion Therapeutics Biopharma Agreement
    Vividion Therapeutics, Inc. · 2023–2023BioPharma Alliance
    VTI 228436-01
  • KP
    DEVELOPMENT OF NEW MODELS OF THYMIC EPITHELIAL TUMORS
    Thymic Carcinoma Center · 2022–2023
    TCC 222040-01
  • MPI
    Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance
    Leukemia & Lymphoma Society · 2018–2023
    LLS 180078-01
  • Co-I
    Harnessing the CRL4 Ubiquitin Ligase for Antagonizing Colorectal Carcinogenesis
    National Cancer Institute · 2017–2023
    R01CA213992-01
  • KP
    Modulation Of Viral Latency In EBV+ Lymphomas To Sensitize Tumors To Immunotherapy
    American Society of Hematology Inc · 2021–2023
    ASH 210413-01
  • PI
    Inghirami Kymera BP
    Kymera Therapeutics, Inc. · 2021–2023BioPharma Alliance
    BP 214958-01
  • PI
    C4 Therapeutics BioPharma
    C4 Therapeutics · 2021–2023BioPharma Alliance
    BP 214989-01
  • Co-I
    Optimization of immune checkpoint inhibition during radiation-induced vaccination in breast cancer
    Breast Cancer Research Foundation · 2019–2022
    BCRF-20-053
  • MPI
    Defining and Targeting the JAK/SYK Pathways in Gamma Delta T-Cell Lymphomas
    National Cancer Institute · 2020–2022 · via Memorial Sloan Kettering Cancer Center
    P50CA192937-05
  • Co-I
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2017–2022
    UL1TR002384-01
  • Sub-PI
    Translational Discovery in Peripheral T-Cell Lymphomas
    Leukemia & Lymphoma Society · 2021–2022 · via Dana-Farber Cancer Institute
    LLS 7026-21
  • KP
    Targeting Unmet Clinical Needs for B-Cell Lymphoma
    Leukemia & Lymphoma Society · 2016–2021
    7012-16 CORE A
  • PI
    PRMT5 Proposal in Lymphoproliferative Disorders
    Prelude Therapeutics Incorporated · 2020–2021BioPharma Alliance
    PTI 211559-01
  • Sub-PI
    No. S19-049 for the Acquisition of Refractory Biospecimens (PTCL cases)
    National Cancer Institute · 2019–2021 · via Memorial Sloan Kettering Cancer Center
    HHSN261201500003I
  • PI
    Identification of transcriptional determinants of asparaginase sensitivity in leukemias
    Starr Cancer Consortium · 2019–2021
    I12-0063
  • Co-I
    Targeting the Epithelial to Mesenchymal Transition-Related Chemoresistance in Breast Cancer
    National Cancer Institute · 2016–2021
    R01CA205418-03
  • Sub-PI
    Core C: Translational Discovery in Peripheral T-Cell Lymphomas
    Leukemia & Lymphoma Society · 2015–2020 · via Dana-Farber Cancer Institute
    7011-16 CORE C
  • Sub-PI
    Project 1: Translational Discovery in Peripheral T-Cell Lymphomas
    Leukemia & Lymphoma Society · 2015–2020 · via Dana-Farber Cancer Institute
    7011-16 PROJECT 1
  • PI
    SRA Amendment No. 1 extending term to 2020.
    Affimed · 2019–2020Contract
    SRA 193797-01
  • Co-I
    Targeting epigenetic regulator PRC2 as a therapy for established metastasis
    METAvivor Research and Support, Inc. · 2018–2020
    MRS 183299-01
  • MPI
    LETSSGO: LYMPHOMA-ON-CHIP ENGINEERED TECHNOLOGY FOR SINGLE-ORGANOID SEQUENCING AND GENOMICS
    National Cancer Institute · 2017–2020 · via Cornell University - Ithaca
    R33CA212968-03
  • Co-I
    Optimization of Immune Checkpoint Inhibition During Radiation-Induced Vaccination in Breast Cancer
    Breast Cancer Research Foundation · 2018–2019
    BCRF 17-053
  • Co-I
    A rational immuno-oncology strategy to target tumor associated stromal cells using untibodies.
    Sanofi S.A. · 2016–2017Contract
    Sanofi RAA

Clinical research

2 studies

Active

2 studies
  • PI
    Retrospective longitudinal tissue evaluation of lung cancer patients who receive standard/immune-based, post-operative systemic therapy, and/or who undergo recurrence or progression
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
  • PI
    Evaluation of the BD OneFlow Acute Leukemia Panel (BD OneFlow ALOT, BCP-ALL T1, and AML T1-T4) on the BD FACSLyric Flow Cytometer using Leftover, De-identified Specimens
    Becton, Dickinson and Company · OPEN TO ACCRUAL (as of 2022)

Available technologies

1 technologyView full WCM portfolio ↗

News mentions

1 mentionView all WCM news ↗

Mentoring

3 menteesAll publications with mentees →

External relationships

Other

Daiichi Sankyo, Inc.